About this Calculator

The Concerta Dose Calculator provides dosing guidance based on the official FDA-approved prescribing information. It is designed to assist qualified healthcare professionals in determining appropriate starting doses, titration schedules, and conversion strategies from immediate-release (IR) methylphenidate for patients with Attention-Deficit/Hyperactivity Disorder (ADHD).

Disclaimer: This information is for educational purposes and is not a substitute for clinical judgment. Dosing must be individualized by a licensed healthcare provider.

Understanding the Outputs

The calculator provides tailored recommendations based on the patient's age, weight, and treatment history. Key outputs include:

• Starting Dose: Recommends the appropriate initial once-daily dose for patients new to stimulants (stimulant-naïve). This is typically 18 mg for children/adolescents and 18 mg or 36 mg for adults.
• Titration Schedule: Suggests dose adjustments in 18 mg increments at weekly intervals, based on clinical response and tolerability.
• Maximum Dose: Notes the maximum recommended daily dose, which is 54 mg for children (6-12 years) and 72 mg for adolescents and adults.
• Conversion Dose: For patients switching from IR methylphenidate, it calculates an equivalent starting dose of Concerta based on their total daily IR dose.

How to Use the Calculator

To generate a dosing recommendation, input the following clinical data:

• Age: The patient's age in years. The calculator is intended for patients 6 years and older.
• Weight: The patient's body weight. This can be entered in either kilograms (kg) or pounds (lbs). Weight is particularly important for adolescents, as the dose should not exceed 2 mg/kg/day.
• Dosing Scenario: Select the most relevant clinical situation:
  • Initial Titration: For patients who have not previously taken methylphenidate or other stimulants.
  • Conversion from IR Methylphenidate: For patients currently stable on an immediate-release formulation who are switching to Concerta.
  • Dose Adjustment: For patients already taking Concerta who require a dose titration.

Concerta Dosing Overview

Concerta (methylphenidate HCl) extended-release tablets use the OROS® (Osmotic Controlled-Release Oral Delivery System), which provides an initial release of medication followed by a controlled, ascending release over the day. Dosing should always be individualized.

• Administration: Take once daily in the morning, with or without food.
• Swallow Whole: Tablets must be swallowed whole with liquid and should never be chewed, divided, or crushed. Doing so disrupts the extended-release mechanism.
• Titration: Dose may be increased weekly until an optimal clinical response is achieved.

Switching Between Formulations

When converting a patient from immediate-release methylphenidate to Concerta, the starting dose of Concerta is based on the patient's current total daily dose of the IR product. The approved prescribing information provides the following guidance, which this calculator uses:

• IR Dose 5 mg (BID or TID) → Start Concerta 18 mg once daily
• IR Dose 10 mg (BID or TID) → Start Concerta 36 mg once daily
• IR Dose 15 mg (BID or TID) → Start Concerta 54 mg once daily
• IR Dose 20 mg (BID or TID) → Start Concerta 72 mg once daily

This conversion is a starting point, and the dose may need further adjustment based on the patient's response.

Managing a Missed Dose

If a dose of Concerta is missed, the patient should take it as soon as they remember. However, if it is late in the afternoon or evening, they should skip the missed dose and resume their regular schedule the next morning. A double dose should never be taken to make up for a missed one, as this can increase the risk of side effects.

Important Safety Alerts

Concerta has a Boxed Warning regarding its high potential for abuse and dependence. Healthcare providers should assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence throughout treatment.

Other key safety considerations include:

• Monitoring for cardiovascular events, as stimulants can increase blood pressure and heart rate.
• Watching for new or worsening psychiatric symptoms, such as psychosis or mania.
• Informing patients about the "ghost tablet," as the non-dissolvable tablet shell may appear in the stool.

Frequently Asked Questions

What is the maximum dose of Concerta for a child (ages 6-12)?

The maximum recommended daily dose for children aged 6 to 12 is 54 mg.

Can this calculator be used to switch from other stimulants like Adderall XR?

No. This tool is only for converting from immediate-release methylphenidate. Switching from other stimulants requires independent clinical judgment, as direct dose-equivalency is not established.

What does the term "ghost tablet" mean?

Concerta's shell does not dissolve and is eliminated from the body in the stool. This is normal and does not mean the medication was ineffective.

Why is the starting dose different for adults versus children?

The prescribing information provides a standard starting dose of 18 mg for children and adolescents (6-17). For adults, it allows for a starting dose of either 18 mg or 36 mg once daily.

How quickly can the Concerta dose be adjusted?

Dose adjustments can be made in 18 mg increments at approximately one-week intervals to allow for assessment of the patient's response.

What happens if a Concerta tablet is crushed or chewed?

The tablet must be swallowed whole. Crushing, chewing, or dividing it will destroy the extended-release mechanism, leading to a rapid and full release of the dose ("dose dumping"), which can increase the risk of serious side effects.

Can this calculator be used for patients under 6 years old?

No. The safety and effectiveness of Concerta have not been established in children younger than 6 years of age.

Does body weight determine the final Concerta dose?

While weight is a consideration (especially the 2 mg/kg/day limit for adolescents), the final optimal dose is primarily determined by individual clinical response and tolerability, not by weight alone.

References

• 1. CONCERTA® (methylphenidate HCl) Extended-Release Tablets Prescribing Information. Food and Drug Administration.
• 2. Janssen Pharmaceuticals, Inc. CONCERTA Medication Guide.
• 3. Drugs@FDA: CONCERTA (methylphenidate hydrochloride). FDA Application No. 021121.
• 4. Subcommittee on Attention-Deficit/Hyperactivity Disorder, Steering Committee on Quality Improvement and Management, Wolraich, M., et al. (2019). Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Pediatrics, 144(4), e20192528.